Site specific protein modification
AssigneeImmunex Corporation
InventorDean K. Pettit
Life of this patent
Estimating the term…
Abstract
Processes for conjugating proteins with polyethylene glycol are disclosed. The disclosed processes provide modified proteins having little or no decrease in their activity and include the steps of deleting at least one amino acid residue on the protein, replacing the at least one amino acid residue with an amino acid residue that does not react with, polyethylene glycol, and contacting the protein with polyethylene glycol under conditions sufficient to conjugate the polyethylene glycol to the protein. This advantageous retention of a desired protein activity is attributed to the availability of one or more protein binding sites which is unaltered in the conjugation process and thus remains free to interact with a binding partner ligand or cognate subsequent to the conjugation process.
Claims8
A polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.
A polypeptide comprising the amino acid sequence of SEQ ID NO:2.
A polypeptide comprising the amino acid sequence of SEQ ID NO:4.
A polypeptide comprising the amino acid sequence of SEQ ID NO:6.
A process for preparing a modified p75TNFR, said process comprising expressing a nucleic acid in a host cell, the nucleic acid selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.
A process for preparing a modified p75TNFR, said process comprising expressing a nucleic acid that encodes the polypeptide of SEQ ID NO:2 in a host cell.
A process for preparing a modified p75TNFR, said process comprising expressing a nucleic acid that encodes the polypeptide of SEQ ID NO:4 in a host cell.
A process for preparing a modified p75TNFR, said process comprising expressing a nucleic acid that encodes the polypeptide of SEQ ID NO:6 in a host cell.
Dependencies are inferred from the claim text.